Google
×
AllImagesNewsBooks Maps Videos Shopping
Search tools

The role and novel use of natural killer cells in graft-versus-leukemia reactions after allogeneic transplantation

Frontiers
Allogeneic hematopoietic cell transplantation (HCT) has transformed over the past several decades through enhanced supportive care, reduced intensity...
4 months ago

Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation

Frontiers
Over the last decade, the development of multiple strategies to allow the safe transfer from the donor to the patient of high numbers of partially...
7 months ago

Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape

Nature
The quest for treatment-free remission (TFR) and deep molecular response (DMR) in chronic myeloid leukemia (CML) has been profoundly...
41 months ago

Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow

Nature
A recent EBMT paper documented the role of cellular therapy in fighting leukemia at relapse after alloHSCT [1]. In view of that, here,...
61 months ago

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation

Frontiers
Relapse is the main cause of mortality in patients with acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
15 months ago

Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial

Nature
Second HCT with TFT conditioning is feasible and has high anti-leukemic efficacy in chemosensitive or refractory AML relapse after prior allogeneic HCT.
25 months ago

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O010 – O169) | Bone Marrow Transplantation

Nature
QOL is poor in patients with grade III/IV aGVHD. Higher disease severity and inadequate response to steroids had the most negative effects.
39 months ago

The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P578) | Bone Marrow Transplantation

Nature
This study estimated the cost-effectiveness of axi-cel versus SoC from a third-party US payer perspective in the 2L setting.
23 months ago

The 45th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session

Nature
In this study, we analyzaed and compared the results of aplastic anemia patients who had undergone allogeneic stem cell transplantation either from matched...
63 months ago

The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001 – P182) | Bone Marrow Transplantation

Nature
The main objective of our study is to describe outcomes of allo-HCT in patients ≥60 years-old, and to investigate possible prognostic factors.
39 months ago